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INTRODUCTION 
Parkinson‟s disease (PD) is a degenerative disease named after James  
Parkinson (1755-1824) who described this condition in his publication in 
1817 called „Essay on Shaking Palsy.1 Among the neurodegenerative diseases 
it ranks second after Alzheimer‟s disease (AD).  It is more common in the 
elderly, although early onset disease is well known. It has characteristic 
clinical features of bradykinesia and at least one the following: muscular 
rigidity, 4-6Hz. rest tremor and postural instability. Diagnosis is usually made 
by the well validated criteria 
2
 called „UKPDS‟ (UK Parkinson‟s Disease 
Society Brain Bank criteria).  Apart from motor manifestations there are 
number of non-motor manifestations which is a common source of disability 
in PD. These include 
1) neuropsychiatric features such as Cognitive deficits, depression, anxiety 
behavioral changes 2) autonomic symptoms including constipation  3) sleep 
disturbance 4) sensory disturbance such as pain and paresthesia 5) fatigue and 
6) loss of sense of smell. 
Clinicians have ignored cognitive deficits associated with Parkinson‟s 
disease for years. Due to short span of life in the past, it was believed that 
intellect and sensibilities were not affected. The life span has increased now 
with the use of effective treatment that is available making it possible for 
8 
 
patients with PD to live almost as much as non-affected individuals. Last few 
decades has witnessed increasing recognition of mild cognitive impairment 
(M CI) and dementia associated with PD (PD-D). Most patients with 
Idiopathic Parkinson‟s disease have cognitive deficits. But only a portion of 
PD patients develop dementia.  
3
 
Patients with PD usually present with motor features such as 
bradykinesia, rigidity and tremor. However on detailed neuropsychological 
testing, subtle cognitive deficits are almost always present even in early PD. 
3
 
Cognitive profile in PD includes psychomotor slowing, bradyphrenia, apathy, 
impairment in retrieval of memory, set shifting, problem solving, poor 
viusospatial function, fluctuations in attention and concentration, and 
prominent mood and personality changes. 
4
 Language and praxis, however, 
remain largely intact. The cognitive impairment is subtle and does not exhibit 
recognizable functional restriction in daily activities, and may be missed in 
conventional screening and routine higher mental function assessment, but 
they can progress to frank dementia.
1
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REVIEW OF LITERATURE 
Demography of Cognitive impairment in PD 
Compared to age-matched controls, both the prevalence and the 
incidence of cognitive impairment are higher in PD patients. According to 
one study by Janvin et al,
 4
annual rate of conversion of MCI-PD (mild 
cognitive impairment in PD) in to PDD (Parkinson disease dementia) was 
15%. About 60 to 65% of people with mild cognitive impairment due to any 
cause develop clinical dementia during their lifetime.
3
In another study  by 
Caveness et al 
5
26% of 86 PD patients  had MCI, with frontal- executive 
dysfunction being the most common, followed by amnestic deficit.
5
 Among 
patients with PD, incidence rate of dementia was found to be 6 times more 
than in controls. 
6
 In cross sectional studies 
7, 8, 9
  40% of patients with PD 
were associated with dementia. In longitudinal studies 
10
 78% have been 
associated with dementia. Dementia was diagnosed in 62% of patients with 
PD, who did not have this condition at the baseline, compared to 17% of 
controls, during the 5 year follow up. 
6
 
Risk factors for cognitive impairment in PD 
Number of risk factors associated with cognitive deficits in PD have been 
identified, in both prospective and cross-sectional studies. 
11
 
 
10 
 
They are 
1. Age at onset of PD. Overall risk of development of global cognitive 
impairment increases with age. 
2. Rapid eye movement (REM) sleep behavior disorder 12 
3. Subtle involvement of executive functions, poor verbal fluency, and 
poor performance on verbal memory at baseline were independently 
associated with development of dementia. 
4. Poor cognitive scores at baseline 
5. Motor disability severity 
6. Symmetrical disease presentation 
7. Axial involvement, speech impairment and postural imbalance 
8. Patients who were old and had motor symptoms which was quite 
severe at baseline had risk of developing dementia10 times comparing 
to younger patients whose motor symptoms were less severe. 
13
 
9. Confusion or psychosis  while  taking  levodopa treatment 
10. Autonomic failure  when occurring early 
11. Drug-related hallucinations when occurring early 
12. Poor response to dopaminergic treatment 
13. Olfactory tract and the frontal lobe in the close vicinity  are known to 
be related to memory with memory and loss or decreased smell 
sensation can predate development of Parkinson‟s disease dementia 14 
11 
 
Clinical features of cognitive impairment in idiopathic PD 
The main clinical features are 
8, 9, 10, 11
 
Memory:  There can be moderate impairment, retrieval deficits with 
relatively spared storage  
Attention: There can be prominent impairment with fluctuations 
Executive functions can be severely impaired 
Visuospatial functions: There can be early and substantial impairment 
Language: Impaired word finding and verbal fluency is recognized 
Features associated with cognitive impairment in idiopathic PD are 
Motor features: 
 Symmetrical involvement 
Prominent postural instability and gait disorder 
Tremor dominance which is less frequent 
Behavior features 
Apathy 
Hallucinations 
Delusions 
12 
 
Depressive symptoms 
Idiopathic PD can be classified based on cognitive assessment as below 
 Cognitively intact PD 
 Minimal cognitive impairment [MCI-PD] 
 Dementia [PDD] 
Minimal Cognitive Impairment associated with PD (MCI-PD) 
Mild cognitive impairment in PD (PD-MCI) is defined as cognitive 
impairment that is not normal for that age but with normal functional 
activities. Based on modified Peterson criteria, MCI-PD has been classified 
into 
11
 
 Single domain, non-memory related MCI(executive, visuospatial, or 
language) 
 Multiple domain MCI 
 Amnestic type MCI 
It was found that single domain impairment is more common than multiple 
domain involvement. I was also conclusively found that non amnestic more 
often involved than nonamnestic impairment. There was significant 
heterogeneity in the cognitive domain involvement 
8 
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Progression of PD-MCI to PDD 
PD-MCI is known to be a risk factor for PD 
11
.  The majority of PD-MCI 
cases convert to PDD over several years 9. The point prevalence of is about  
30% 
and
 the cumulative prevalence is about 75% for PD patients who survive 
more than 10 years. 
11
 
Parkinson disease dementia (PDD) 
Attention 
 Attention impairment is an early feature of PDD. 
6
 Just like Dementia 
of Lewy body disease [DLB] even in PD with dementia there is early and 
prominent impairment of attention and vigilance. Central processing time is 
prolonged in PDD resulting in longer response durations in measures of 
simple and choice reaction time. 
Executive function: 
 Executive function is the capacity to plan, organize and perform 
behavior that is goal directed 
11
. A deficit of executive function   is a core 
feature of PDD. This deficit occurs early and is prominent throughout the 
course. These deficits involve tasks requiring concept formation, set 
elaboration, set maintenance and problem solving. When compared to 
14 
 
external cued behavior, the internal cued behavior is more affected in patients 
with PDD. 
16
 
Memory 
 In PDD all types of memory is impaired .
11
This includes explicit and 
implicit memory as well asworking memory. The severity and profile of 
impairment varies from that seen in amnestic syndrome .
10
 In PDD 
recognition is significantly better with cues but free recall is affected, which 
means that the new information was stored but could not be readily retrieved. 
The memory stores in PDD patients were found to be correlated with 
executive function test scores. It therefore suggests that memory deficit may 
be due to difficulties in getting hold of memory traces which reflects a 
deficiency in internally cued search strategies, due to dysexecutive syndrome. 
Limbic type memory disorder prevalent in Alzheimer‟s disease (AD) where 
both storage and recall cues are impaired, is contrast to PDD associated 
memory disorder. 
15
 
Language 
 In PD core language functions are relatively preserved. Main feature of 
language dysfunction in PD are impaired verbal fluency and mild anomia. 
When the disease progresses it develops into transcortical type aphasia. 
Dysexecutive syndrome rather than true involvement of language functions is 
15 
 
believed to be the cause of language deficits in PDD, due to impairment of 
self-generated search strategies. Contrastingly aphasia type language 
abnormalities are prominent early in AD. 
10
 
Visuospatial function 
 PDD has another characteristic feature which is early and prominent 
viusospatial function deficit. Impairment of visual perception may be the core 
of the problem as tasks that require viusospatial analysis and orientation are 
found to be the most affected. Visuospatial abstraction and reasoning are 
more affected in PD when comparing to AD. 
Behavior 
Prominent behavioral symptoms and personality change in associated with 
PDD. 
The most common neuropsychiatric symptoms are hallucinations, delusions, 
Depression, anxiety and apathy. Delusions and hallucinations may occur with 
treatment of dopaminergic agents, and occur more frequently with patients 
with dementia. When compared to AD, depressive features and visual 
hallucinations are more common in PD. 
15
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Motor System 
In PDD the motor involvement is more symmetric.  The major difference 
between PD patients with dementia and those without it was a later age of 
onset of motor manifestation in PDD. 
16
 Tremor dominance is associated with 
relative preservation of mental ability; whereas bradykinesia, rigidity and 
postural instability have been correlated with more rapid decline and 
dementiastatus. 
17
 In a study of motor features, postural instability gait 
disorder (PIGD) subtype was found to be overrepresented in PDD in contrast 
to non-demented PD patients. 
18
 It is proposed that L-dopa responsiveness 
diminishes with emergence of cognitive impairment. 
18
 Proposed mechanism 
for this phenomenon is intrinsic striatal alpha synnuclein pathology, loss of 
dopamine D2 and D3 receptors. 
Pathophysiology in PD cognition 
Deficiency of dopamine in the nigrostriatal pathway has initially been 
proposed to be the cause of cognitive impairment in PD .
19
 Many young 
patients however may not show any cognitive impairment even when there is 
severe motor dysfunction. Cognition does not improve with levodopa. This is 
another reason against this theory; in fact it can get worsened especially in 
the later stages. There are reports that cholinergic deficits that occur due to 
degeneration of ascending cholinergic pathways cause cognitive impairment 
and dementia in PD patients. 
16
 
17 
 
 
Above is the proposed neurotransmitter deficits and resulting specific 
cognitive dysfunction 
16 
Pathology
 
 
 
Deficits Effect  
Cholinergic deficit Impairment in frontal dysfunction  
memory and attention  
Dopaminergic deficiency Dysexecutive syndrome 
Noradrenergic deficits Impaired attention 
Serotonergic deficits Depressive mood 
18 
 
 
There have been some controversies in pathologyand type and the site 
seen in PD dementia. Three types of pathology been invoked, namely in 
subcortical structures, notably dopaminergic neuronal loss in substantia nigra 
(SN) and limbic and cortical areas. 
In PD, pathological changes follow an ascending order, starting from 
brain stem also anterior olfactory nuclei, and then affecting cortical areas 
19
. 
The spread of this kind pathologically from brainstem followed by the limbic 
and later neocortical areas may explain why dementia usually develops 
relatively late in classic PD. 
19
 
Genetics 
Rare form of familial PD with dementia occurs. Major component of 
lewy body being alpha synnuclein, when expressed in excess, is important for 
19 
 
development of dementia. ApoE2 allele when present increases the likelihood 
of dementia in patients with PD as against those with AD where its presence 
is protective. 
20
 
Imaging 
Several non-specific features have been described in structural and 
functional brain imaging. 
21, 22  
When compared to normal controls, in PDD 
patients widespread areas of cortical atrophy were found in both frontal 
temporal and lobe and left parietal lobe. 
23,24,25,26
 Grey matter reductions were 
found in frontal, temporal and parietal limbic lobes in these patients. In AD 
there is more severe atrophy of temporal lobe including hippocampal and 
para hippocampal areas, whereas in PDD there was severe atrophy of 
thalamus and occipital lobe .
27
 Enlargement of ventricles and caudate atrophy 
are other structural changes in cognitive impairment of PD  
How to diagnose cognitive deficits in PD? 
Diagnosing cognitive deficits in PD is made difficult by confounding 
factors such as  
 Apparent language dysfunction as a consequence of motor dysfunction 
 Difficulty in deciding if impairment of daily activities is due to motor 
or cognitive dysfunction. 
 Drug effects complicating diagnostic process. 
20 
 
Steps in diagnosing suspected dementia in PD: 
The first step is Diagnosing dementia: differentiating dementia from 
pseudodementia of depression, delirium, and side effect of drugs. As a next 
step one has to differentiate Dementia in atypical Parkinsonism; PD with AD 
other dementias due to Vascular disease, tumor, Normal pressure 
hydrocephalus (NPH) and metabolic disease such as thyroid disease. As a 
third step, other conditions like essential tremor which can be associated with 
cognitive impairment. 
NEUROPSYCHOLOGICAL TESTS 
1. Mini-Mental State Examination 
Several bedside tests are used in assessing the mental status. However, still 
the most commonly used test is Mini-mental state Examination (MMSE) by 
Folstein et al. 
28 
Maximum points given for MMSE are 30. For orientation in 
time: i.e. date, day, month, year and season 5 points are given; 5 points for 
orientation to place viz. floor, hospital, town, state and country.; 5 points for 
attention by serial 7 test or spelling the word “WORLD” backwards.; 3 points 
given for registration and 3 points for recall of the 3 items after a gap of 5 
minutes. For naming watch and pencil, 2 points are given; one point for 
repetition of sentence; a total of 3 points is given for 3 stage command; one 
point for command  for writing asking patient to close eyes,  1 point is given 
21 
 
to write  a sentence and one point is given for copying two intersecting 
pentagons. The low normal cut off is estimated to be 29 for college graduates, 
23 for elementary or junior high school completers and 19 for uneducated 
people.  
29 
Advantages of MMSE: a) it requires limited time b) it is useful for 
documenting disability assessments and following drug trials and c) it is a 
useful screening test. 
Disadvantages: a) the score depends on the educational status of population 
studied b) the test is biased to orientation and language which is less affected 
in frontal lobe involvement and right hemispheric lesion. c) It cannot 
differentiate diffuse from focal lesion.
28,31
 
2. Addenbrookes’s Cognitive Examination- Revised (ACE-R). 
Devised from the Addenbrookes‟s hospital, Cambridge, UK, it is designed to 
diagnose and classify different types of dementia like Alzheimer‟s dementia 
(AD) and fronto-temporal dementia (FTD) and, without using any specialized 
equipment
30. 
It includes MMSE and in addition language, memory and visuo 
spatial components. It consists of orientation (10 points) memory (35), 
attention (8), language (28), visuospatial ability(5) and verbal fluency (14) 
with the total maximum score of 100. The score is not influenced by age, sex 
or education. 
22 
 
3. Montreal Cognitive examination (MoCA) 
The Montreal cognitive Assessment (MoCA) was developed as a quick 
screening instrument for mild cognitive deficit 
31,32
. It assesses different 
cognitive domains namelyexecutive functions, attention and 
concentration,language, memory, visuoconstrucitonal skills, conceptual 
thinking, calculations and orientation. It would take 10 minutes to administer 
the test. Total maximum score is 30 points; a score of 26 or above is 
considered normal. 
4. Frontal Assessment Battery. 
This evaluates various executive cognitive functions by a battery of six 
subtests. 
33,34  
By this score the patient is evaluated which demonstrates the 
severity of dysexecutive function if any. The FAB subtests are very well 
correlated with frontal lobe damage caused by various etiology and are well 
demonstrated by Pet study of frontal lobe metabolism.
30
  The test is also 
studied in frontal lobe dysfunction due to PD, PSP (progressive supranuclear 
palsy, FTD (Frontotempoorral dementia), MSA (multiple system atrophy) 
and also assessed the severity of dysfunctions. 
34
FAB also has good 
psychometric properties because of the optimal inter rater reliability, 
concurrent validity and internal consistency.  Guedji et al found in their 
recent study 
34 
that in Neuroimaging, FAB performance significantly 
correlates with perfusion in prefrontal cortex. 
23 
 
FAB test is done approximately within 10 minutes.
33
 It has six subtests and 
each subtest has score from 0 (minimum) to 3 (maximum score). The total 
maximum score is 18. 
Subtests of FAB: 
a. Conceptualization: 
It is based on traditional similarities. This evaluates the patient‟s ability to 
generate similarities between: 1) orange-banana 2) chair- table, 3) daisy-rose-
tulip. The examiner asks: in what way they are alike. The patient cannot be 
helped in the other items. Full correct responses are fruits, furniture, and 
flowers respectively. Each right response is associated to one credit (none 
correct: 0, one correct= 1, two correct=2; three correct= 3). 
b. Mental flexibility  
The patient has to recall as many words as he can, beginning with the letter S 
in aone minute trial e.g. “say as many words as you can, beginning with the 
letter S; any words except surnames or proper nouns”. Each correct word is 
scored as 1 point. The score in mental flexibility may be 0 (< 3 words), 1 (3 
to 5 words), 2 (6 to 9 words), or 3 (> 9 words). 
 
 
24 
 
c. Motor programming 
The patient is explained by the examiner about Luria‟s „fist- palm- edge‟ 
motor series and repeated for three times. The patient is asked to copy the 
examiner as he does the sequence, and is asked to do independently. The 
patient who cannot perform 3 correct consecutive series even with the 
examiner‟s help receives no point. Patient who is unable to do on own but is 
able to do with the examiner‟s help receives 1point. 2 points are given to 
patient who performs at least three correct consecutive series alone, and 3 
points given for six correct consecutive series.  
d.Go- no- go test. This is based on inhibitory control. The subject should 
inhibit what he has just learned and is required to tap once when hearing a 
single tap. A series of there trials as 1-1-1 is given. After this, the examiner 
should ask the patient not to tap when hearing two taps. The examiner does 
there trials as 2-2-2. After this the examiner taps this sequence 1-1-2-1-2-2-2-
1-1-2. The points are given as 0,1,2,3 respectively. 
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AIM OF THE STUDY 
 
1. To identify the range of cognitive impairment if any inpatients with 
Idiopathic Parkinson‟s disease. 
 
2. To identify subclinical cognitive impairment in newly diagnosed 
idiopathic Parkinson‟s disease. 
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MATERIALS AND METHODS 
100 patients with Idiopathic Parkinson‟s disease who attended Neurological 
services at Rajiv Gandhi Govt. General hospital, Chennai were included for 
the study. 
Study design: Single centre, non- randomized prospective study 
Study period: Study was conducted between September 2012 and January 
2014. Ethical committee approval was obtained. 
Inclusion criteria 
Newly diagnosed patients with Idiopathic Parkinson‟s disease aged between 
55and 75 years and not started on anti parkinsonian drugs were included for 
the study. 
 
Exclusion criteria 
1. Very ill patients (moribund state) 
2. Presence of depression ( pseudodementia), behavior disorders or 
delirium 
3. Symptomatic parkinsonism dementia complex [vascular,tumor,NPH] 
4. Coincident degenerative dementia like AD 
27 
 
5. Degenerative diseases presenting with Parkinsonism and dementia 
namely Progressive supranuclear palsy (PSP), Cortico basal 
degeneration (CBD) and Dementia in Lewy body disease (DLB). 
6. Vascular  risk factors  like Diabetes mellitus, Hypertension and also 
history of stroke 
Following steps were used 
Step 1: Written consent was obtained for all patients (Annexure).  
Step 2: Detailed history including demographic details, thorough 
neurological examination including cognitive examination of lobar functions 
and were done for all patients,  
Step 3: Idiopathic Parkinson‟s disease was diagnosed by applying UKPDS 
Brain Bank Clinical Criteria. (Annexure II) 
Step 4: Patients with other causes of Parkinsonism were excluded by clinical 
examination and investigations including brain imaging. Patients having 
comorbid illness such as severe hypertension, diabetes or other neurological 
illnesses were excluded.  
Step 5:  Severity of motor disability was rated on Hoehn and Yahr scale. 
(Annexure III) 
Step 5. The cognitive assessment was done by Neuropsychological tests 
MMSE (Mini mental state examination), ACE-R (Addenbrookes‟s cognitive 
28 
 
examination-Revised), MOCA (Montreal Cognitive Assessment) and FAB 
(Frontal assessment battery test).  
Step 6: Administering Movement Disorder Society Task Force Criteria 
(Annexure IV) to classify Idiopathic Parkinson‟s disease patients into 
cognitively intact, PD-MCI and PDD. 
SPSS software was used for statistical analysis. The study was analyzed by 
Chi square test and P value was obtained. 
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RESULTS AND ANALYSIS 
The total number of patients included in the study was 100.  The 
parameters analysed were 1) Age 2) Duration of illness 3) Educational status 
4) Hoehn and Yahr stage 5) UPDRS score. Each of these parameters was 
compared with the individual cognitive scalenamely MMSE, ACE-R scale, 
MoCA and FAB test. Other non- motor manifestations quoted in the review 
of literature like behavioural disturbances, psychosis, mood disorders, sleep 
disorders, autonomic disturbances, sensory disturbances and sensation of 
smell are beyond the scope of this study, and therefore were not analyzed. 
Out of 100 patients, 61 (61%) were males and 39 (39%) females (Fig. 
1) 
Figure 1: Sex distribution
 
61%
39%
Sex distribution
Males
females
30 
 
Figure 2: Age distribution of patients 
:  
Figure 3. Educational status of patients 
 
Out of the total number of 100 patients,  20(20%) were illiterate or studied up 
to 5
th
 standard, 76(76%) studied up to secondary school and 4 (4%) were 
degree holders. 
29%
45%
26%
Age distribution
55-60 yrs 61-70 yrs 71-75 yrs
20%
76%
4%
Educational status
Illiterate & Elementary school Secondary school Degree holder
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Figure 4 : Duratin of illness 
 
Out of 100 patients 26 patients (26%) had duration of less than 5 years, 22% 
had  
duration of 5-10 years and 52% had duration more than 10 years (Figure 4) 
 
 
 
  
22%
52%
26%
0%
Duration of illness 
< 5 years 5-10 years > 10 years
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RESULTS OF COGNITIVE EXAMINATION:  
Analysis of MMSE in PD 
Figure 5: Analysis of MMSE in PD 
 
The MMSE was < 23 in 63% of patents with PD and > 23 in 37% of patients.   
 
 
 
 
37%
63%
MMSE IN PD
MMSE < 23 MMSE > 23
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Figure 6: Sex distribution and MMSE 
 
In males less than 23 score on MMSE was obtained by 32.8% of patients and 
score more than 23 was obtained by 67% of patients. In comparison, in 
females score less than 23 was obtained by 43.8% and score more than 23 
was obtained by 56.4% of patients. (Fig. 6) 
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Figure-7: Addenbrookes cognitive examination total score 
 
In Addenbrooke‟s cognitive examination out 100 patients studied 31 patients 
(31%) scored less than 60, 54% scored 60-80 range and 23% scored more 
than 80. The highest score is seen in the youngest age group of 50 to 55 years 
in PD patients and poorest score is seen in oldest age group of 71- 75 ( fig. 8) 
 
 
 
 
  
23%
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Addenbrookes cognitive examination total 
score
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PARAMETER 1: Age  
Table 1. Age distribution in PD patients and MMSE 
 
Age group MMSE 
< 23 >23 
55-60 9 (25%) 27(75%) 
 61-70 18(37.5%) 30(62.5%) 
71-75 10(62.5%) 6 (37.5%) 
 
Chi-square value: 6.692; P=0.035 (P<0.05) Significant  
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Figure 8: Age group versus ACE-R total score 
 
The comparison of age group with ACE –R score is given in Table 2 below. 
It is clear that the ACE- R cognitive score is better in younger age group of 
PD patients and worsens with increasing age. 
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Table 2 
Age Group No of pts. with ACE-R 
score attention and 
orientation 
Total 
<12 >12 
55-6  (10) 27.8% (26)72.2% 36(100%) 
61-70 (20) 41.7% (28) 58.3% 48(100%) 
71-75 (11)68.8% (5) 31.3% 16(100%) 
Chi-square value: 7.704; P=0.021 (P<0.05) Significant  
In Addenbrooke„s cognitive examination maximum score for attention and 
orientation was 18. It is seen that in the age group of 55- 60 years, 72% who 
scored more than 12 points when compared only 27.8%  in age group 71-75 
years. 
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Figure 9: 
 
Chi-square value: 6.692; P=0.035 (P<0.05) Significant  
In Addrenbrooke„s cognitive examination total score for memory was 
categorized into those scoring less than and those scoring more than 18. As 
above (Fig.9) with increasing age more patients scored less than 18 on this 
test. 
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Age group vs. ACE-R Fluency 
In Addenbrooke's cognition total scoring for verbal fluency was 14.While in 
the age group 55-60 years equal number of patients with score < 8 and > 8 
points, in the older age group scores of <8 was more than scores of >8 
(Fig.10) 
Figure 10. Age group vs. ACE- R fluency  
 
5) Maximum number of score for language testing in Addenbrooke„s scale 
was 26.  Age group 55-60 8 patients (22%) scored language score less than 
18whereas the score was 29.6% for the age group 61-70 years and 56.8% for 
the age group 71-75 years (Fig- 11).  
50.00%
54.20%
56.80%
50%
48.80%
48.30%
55-60 years 61-70 years 71-75 years
Age group vs. ACE- R fluency 
score <8 score >8
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Figure 11. Age Group in years vs. ACE-R Language 
 
As far as the ACE-R language testing is concerned although there is decline 
in ACE-R score with increasing age. However as seen in table above this is 
smooth and marginal and not as marked as in other cognitive domains.  
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Age and ACE-R visuospatial  
Figure 12. 
 
Chi-square value: 5.6; 27 P=0.045 (P<0.05) Significant  
Older the age group in PD patients lesser ACE-R Visospatial score as in 
Fig.12 
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Figure 13: Age group and MoCA 
 
When age group is compared with the cognitive test MoCA, it is found that in 
younger age group of 55-60 years more patients (77.8%) had scores more 
than 23 when compared to patients in the older age groups and only 22% 
scored less than 23  
 
 
 
22.20%
37.50%
43.80%
77.80%
62.50%
56.30%
Age group 55-60 years 61-70 years 71=75 years
Age group and 
MOCA
score < 23 score >23
43 
 
Figure 14.Age group vs. FAB total score 
 
Chi-square value: 41.01 P=0.040(P<0.05) Significant 
In the above figure increasing age shows reduction in total FAB score. 
Figure 15: Education and MMSE 
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Figure 16: Education and ACE-R total Score 
 
Chi-square value 14.834 P=0.005 (P<0.05) Significant 
Figure 17: Education and MoCA 
 
Chi-square value 4.842 P=0.045 (P<0.05) Significant 
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Figure 18: Education vs. FAB total score 
 
 
Chi-square value: 11.729 P=0.003 (P<0.05) Significant 
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PARAMETER 2. Duration of illness 
Figure 19:Duration of illness vs. MMSE 
 
Chi-square value: 53.425, P=0.001 (P<0.05) Significant 
 
From the above figure it is seen that MMSE score progressively worsens with 
the longer duration of PD 
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Figure 20: Duration of illness in years * ACE-R Total score 
 
 
 Chi-square value: 92.27, P=0.001 (P<0.05) Significant  
 
 
 
  
 
 
 
 
 
 
 
 
 
4.50%
11.50%
100%
18.20%
61.50%
0%
77.30%
26.90%
0.00%
Duration < 5 yrs 5-10 yrs > 10 yrs
Durartion of illness vs. ACE-R total
ACE-R total < 60 61-80 81-100
48 
 
Figure 21: Duration of illness in years * MOCA 
 
Chi-square value: 42.358, P=0.001 (P<0.05) Significant  
In the above figure it is seen that longer the duration of illness, lesser is the 
cognitive score. 
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Figure 22: Duration of illness vs. FAB total score 
 
 
 Chi-square value: 57.542, P=0.001 (P<0.05) Significant  
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PARAMETER 3. Hoehn & Yahr scale 
Figure 23: Hoehn & Yahr scale versus MMSE 
 
Chi-square value: 28.2; P=0.001, (P<0.05) Significant  
The MMSE score was higher in more abled patients with PD (lesser score on 
Hoehn & Yahr) and lower MMSE score was found in less abled (higher score 
on Hoehn & Yahr scale) 
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Hoehn and Yahr scale and ACE-R total score 
In the Figure 24, it is shown that the ACE-R cognitive score is higher in more 
abled (low Hoehn and Yahr score) patients and lower cognitive score seen in 
less abled patients (high Hoehn andYahr score) 
Figure 24. Hoehn and Yahr and ACE_R total score 
 
Chi square 37.308, P value= 0.001 (p < 0.05), significant 
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Figure 25:Hoehn & Yahr scale and MoCA scoring 
 
Chi-square value: 26.48. P=0.001 (P<0.05) Significant 
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Figure 26: Hoehn & Yahr vs. FAB total score 
 
Chi-square value: 7.704; P=0.021 (P<0.05) Significant  
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PARAMETER 4: UPDRS 
Figure 27: UPDRS and MMSE 
 
Chi-square value: 30.304, P=0.001 (P<0.05) Significant  
In above table the UPDRS score is inversely proportional to MMSE score 
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Figure 28: UPDRS and ACE-R total score 
 
Chi-square value: 65.548, P=0.001 (P<0.05) Significant  
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Figure 29: UPDRS and MOCA 
 
Chi-square value: 18.039, P=0.001 (P<0.05) Significant  
UPDRS vs FAB total score: As illustrated in the figure below, patients with 
higher score on UPDRS indicating more severe illness have performed with 
lower FAB total score 
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Figure 30: UPDRS vs. FAB total score 
 
Chi-square value: 22.132, P=0.001 (P<0.05) Significant  
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Table: 3 UPDRS * all cognitive tests 
UPDRS 
score 
MMSE ACE-R  MoCA FAB 
< 23 23-27 28- 30 < 60 61 - 80 81- 100 <23 >23 < 12 >12 
< 30 2.0% 18% 80% 3.2% 12.9% 83.9% 3.2% 96% 3.2% 96% 
31-60 50.85 10.% 39.2% 43.1% 49.2% 7.7% 46.2% 53.8% 38% 61.5% 
>60 80% 20% 0% 100% 0% 0% 50% 50% 100% 0 % 
 
UPDRS score was analyzed with the cognitive tests viz. MMSE, ACE-R, 
MOCA and FAB test. In patients with low UPDRS (< 30), it was found that 
more patients had higher score.  This was particularly so with FAB test (96%) 
and MoCA (96%) followed by ACE-R (83.9%) and finally MMSE (80%). 
Conversely in patients with UPDRS score > 60, more patients had lower 
score and once again it was marked for FAB test with none getting score 
more than 12 in this group. 
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DISCUSSSION 
The total number of patients included in this study was 100. Majority 
of patients were males (61%) and the male/female ratio was 2.2: 1 which is 
more than in previous studies,
31
 where it ranged from 1.4:1 to 1.6:1. One of 
the possible reasons for this could be that women of the social group 
attending this hospital may not seek medical help as much as men, as they 
have to leave behind household activities to come to hospital. The mean age 
of patients with PD was 64.  
Out of the total 100 patients 20% were illiterate or studied only up to 
elementary school. The majority (76%) studied up to secondary school and 
few (4%) were degree holders. 
It was reported by Caviness JN et al 
5
 that 21% of the 86 patients with 
PD had MCI. Prevalence of dementia in PD population was found by various 
population studies to be 40% to 80%.
3, 4, 5, 8
   Similar to these observations in 
our study too76% of PD patients had cognitive deficits; the remaining 24% 
had no cognitive deficits.  Out of 76% patients with cognitive deficits 44% 
had MCI and 30 % patients had dementia (PDD).   
The MMSE score was less than 23 in 63% of patients with PD and 
more than 23 in 37% of studied population. The mean MMSE score was 
24%. 
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Effect of age on the cognitive testing: 
 There is inverse relationship between age and cognitive decline as 
illustrated in Table 1. with more subjects in age group of 71-75 showing 
score less than 23 on MMSE compared to age group of  55- 60 
 On comparing the age group with that of total ACE-R score (Fig.2), it 
is clear that the ACE- R cognitive score is better in younger age group of PD 
patients (47% having score more than 80) and worsens with increasing age 
(12.5% having score more than 80).  This is consistent with Pillon Bet al 
study, 
16
 where 45% of patients aged less than 60 scored more than 80 on 
ACE-R score. In Addenbrooke‟s cognitive exam for attention and orientation, 
in the age group of 55- 60 years, 72% scored more than 12 points when 
compared to only 27.8% in age group 71-75 years. Our study is similar to that 
of Pillon B et al study in this aspect. 
16
Mohr et al‟s study however did not 
show disturbance of attention and concentration.
44
 
When taking memory component of ACE-R, with increasing age, more 
patients scored less than 18 which is the cut off for cognitive impairment on 
this test, and this was statistically significant. In the verbal fluency 
component of ACE-R, with total possible score of 14, 50 % the patients 
younger than 55 scored above 8, whereas 48% of age group 71- 75 years 
score more than 8. This particular domain does not have big difference 
compare to other components of ACE-R.  
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In the language front of ACE-R, although there is decline in ACE-R score 
with increasing age, this is smooth and marginal and not as marked as in 
other cognitive domains. This is consistent with previous studies 
30 
by Dudas 
B et al. Similarly older age groups had progressively fewer score for 
visuospatial component for ACE-R cognitive examination (fig.12) which had 
statistical significance. 
The FAB test has total score of 18, testing frontal lobe functions. With 
cut off  12 being  kept for cognitive impairment, only 22% showed evidence 
of cognitive impairment in patients less than 60 years of age, while 50% in 
the older age group of 71to 75 years had that score, inferring the frontal lobe 
functions are particularly compromised in the Parkinson‟s disease patients 
more than  language or fluency. This is similar to the study by Mohr et al. 
44
 
 Like other cognitive tests done in this study, the MoCA test too 
showed decline in cognitive score in the older age group, with score less than 
23 increasing with age and score more than 23 decreasing with age (fig. 13). 
This correlates well with previous study by Zadikoff C et al. 
31
 
Duration of illness and PD cognition: 
The duration of illness varied from 1½ to 13 years. The majority of 
patients (52%) fell in the category of duration 5 to 10 years.   
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While more than 90% of patients with illness less than 5 years  scored 
more than 23 on MMSE (Fig.19), exactly opposite effect was seen in patients 
with duration more than 10 years (i.e. more than 90% scored less than 23 in 
this group). This clearly suggests that cognitive impairment is much more 
prevalent with longer duration of illness. These findings are comparable to 
the longitudinal studies by Reid WG et al,
36 
where62% of patients had 
dementia in the 5 year follow up. Our study is also consistent with the 
prospective study by Aarsland D et al 
37 
in whose study the cumulative 
incidence of dementia varied from 28% at baseline to 78% at 8 years follow 
up was observed. 
When ACE-R total score was considered, in  patients with  duration of 
illness  less than 5 years, only 4.5%  had ACE-R score less than 60( can be 
taken as  cut off for dementia); whereas all the patients  whose illness lasted 
more than 10 years had score less than 60, which is highly significant. 
Similarly, significant but less dramatic difference was seen with MoCA 
cognitive testing when it was compared with the duration of illness. FAB 
score also showed more cognitive decline in patients with longer duration of 
illness. 
Education and cognition in patients with PD:  
Majority (76%) of patients in this study had completed secondary 
school.One fifth (20%) were either illiterate or studied only up to elementary 
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school, and only 4%were degree holders. When MMSE score was usednone 
of graduates scored less than 23, while 60% of illiterate/elementary school 
educated patients had this score of less than 23 and this was statistically 
significant. Education had very similar effect on cognition using ACE-R 
memory scoring. The FAB testalso showed almost similar results with none 
of the graduates scoring less than 12 (Fig.18). This is consistent with study by 
Guedj et al. 
34
Similar trends is seen when the MoCA test was used, as is seen 
in earlier study 
31 
and this was statistically significant. However this was less 
so compared to other cognitive scales used.  
Effect of UPDRS (Unified Parkinson’s Disease Rating Scale) on cognition 
UPDRS is the most commonly used rating scale in PD.
1
 It tests the 
motor functions, activities of daily living, and non-motor functions of PD 
including cognition. Since it includes cognition, it is expected that patients 
with higher score of UPDRS will fare worse on other cognitive tests. Giving 
allowance for this, there was statistically significant effect of UPDRS on 
MMSE. All patients scoring less than 30 on UPDRS (less severely affected) 
had MMSE score of more than 23, while all of those with UPDRS score more 
than 60 had MMSE score of less than 23.  
All patients with UPDRS scale of more than 60 (more affected 
individuals) had ACE-R total cognitive scoring of less than 60 which could 
be taken as cut off for dementia. UPDRS had similar effect on MoCA which 
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is another cognitive tool, with more affected PD (UPDRS > 60) individuals 
scoring less the 23 on MoCA.  
Hoehn & Yahr scale and cognition: 
In patients with advanced disease with Hoehn& Yahr scale   4 to 5, 
none had ACE-R score of more than 80.  Majority (93%) of this category of 
PD patients had MMSE less than 23 consistent with PDD (Parkinson‟s 
disease dementia). Similar trend was seen when Hoehn & Yahr scale   was 
used to compare MoCA cognitive scale. Here 87% in the Hoehn and Yahr 
category of 4 to 5 (advanced disease), the MoCA score was less than 23 
indicating significant cognitive decline. Similar effect was seen when Hoehn 
and Yahr scaling was compared to FAB cognitive test. Thus there is greater 
prevalence of cognitive impairment in patients with more advanced disease as 
assessed by Hoehn and Yahr staging. This is consistent with previous studies 
of Janven et al, 
4
 where 90% of patients with Hoehn and Yahr of 4 to 5 scored 
less than 23 on MMSE. 
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CONCLUSION 
1) Patients with Parkinson‟s disease were found to have cognitive 
impairment on formal neuropsychological testing, though they do not 
show functional restriction in activities of daily living. 
2) There is clear linear relationship between age of patients and duration of 
illness in developing cognitive impairment.  
3) Mild cognitive impairment is seen in early stages of Parkinson‟s disease. 
This is observed even in patients with low score for UPDRS and Hoehn 
and Yahr scales. This trend is reflected across all domains of cognitive 
testing used.  This is particularly so with the frontal lobe functions and 
less so with testing for fluency and language.   
4) Frank dementia however, was found only in proportion of patients 
especially those with more advanced disease. 
5) This study highlights the importance of screening of cognition in patients 
with Parkinson‟s disease. If cognitive impairment is found, it will help to 
intervene in the early stages of the illness. 
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ABBREVIATIONS 
 
AD          -  Alzheimer‟s Disease 
DLB            -  Dementia with Lewy Body disease 
FAB  -  Frontal Assessment Battery  
HYS       -  Hoehn and Yahr Staging 
MCI   -  Minimal Cognitive Impairment 
MMSE       -  Mini Mental State Examination 
MoCA -  Montreal Cognitive Assessment 
PD  -  Parkinson‟s Disease 
PDD  -  Parkinson‟s Disease Dementia 
UPDRS -  Unified Parkinson‟s disease Rating Scale 
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PROFORMA 
 
Name          Age  Sex 
Education       Occupation 
Address 
OP No.       MIN No. 
Duration of illness; 
Presenting complaints 
 
Family history 
Past history 
Diabetes: Y/N     Hypertension  Y/N   CAD 
Y/N 
Tuberculosis Y/N    CKD:  Y/N    CVA: 
Y/N 
Personal History 
Social history: Married Y/N     Living with 
Alcohol      Smoking 
CLINICAL FEATURES 
PR:   BP:    CVS    RS 
HMF: 
MMSE Score: 
Executive dysfunction: Y/N    Apathy Y/N 
Memory:Y/N (working, recent, remote) 
Speech: dysarthria: Y/N 
Language: motor/ sensory 
Reading/writing/ copying 
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Apraxia 
Ideational Y/N     Ideomotor Y/N 
Dressing Y/N      Constructional Y/N 
R/L confusion Y/N     Hemineglect Y/N 
Hemianopia/ Quadrantanopia Y/N   Delusion / hallucination 
UPDRS scale 
Modified Hoehn and Yahr staging (0-5) 
Cognitive assessment scales: 
 ACE-R ( Addenbrookes‟ cognitive assessment) 
 MoCA (Montreal cognitive assessment) 
CRANIAL NERVES 
Spinomotor system 
Exrapyramidal system 
Cerebellar system 
Sensory system 
Gait  
Spine and cranium 
INVETIGATIONS 
Hematology TC:  DC: P  L E B Hb  ESR 
Sugar Urea Creatinine Na K 
ECG:    CXR 
Cardiac evaluation 
CT BRAIN: 
MRI BRAIN; 
Other investigations: 
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PATIENT CONSENT FORM 
Study Details: To undergo Cognitive function assessment in patients with Parkinson‟s 
disease. 
Study Centre: Rajiv Gandhi Govt. GeneralHospital, Madras Medical College, Chennai- 
600003 
 Patient may check  these boxes  
I confirm that I have understood the purpose of procedure for the above study  
I have the opportunity to ask questions and all my questions and doubts have been 
answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time without giving reason, without my legal rights being affected. 
I understand that the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the study. 
I agree to this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I agree 
not to restrict the use of any data or results that arisefrom the study. 
I agree to take part in the above study and to comply with the instructions given during the 
study and faithfully cooperate with the study team and to immediately inform the study 
staff if I suffer from any deterioration in my health or wellbeing or any unexpected or 
unusual symptoms. 
I hereby give permission to undergo complete clinical examination including tests for 
cognitive function and diagnostic tests. 
I hereby consent to participate in this study. 
 
 
Signature/ thumb impression 
Patient name and address:     Place 
        Date: 
 
Signature of investigator:     Plaice 
Study investigator‟s name     Date 
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UKPDS BRAIN BANK CLINICAL DIAGNOSTIC CRITERIA 
  STEP 1: Diagnosis of Parkinsonian syndrome 
o Bradykinesia [slowness of initiation of voluntary with progressive 
reduction in speed and amplitude of repetitive action] 
o And at least one of the following  
            Muscular rigidity 
            4-6 Hz rest tremors 
            Postural instability not caused by primary visual, vestibular, cerebellar 
or proprioceptive dysfunction. 
STEP 2: Exclusion criteria for Parkinson’s disease 
o h/o repeated strokes: stepwise progression of  Parkinsonian features 
o h/o repeated head injury 
o h/o definite encephalitis 
o oculogyric crisis 
o neuroleptic treatment at onset of symptoms 
o more than one affected relative 
o sustained remission 
o strictly unilateral features after 3 years 
o supranuclear gaze palsy 
o cerebellar signs 
o early severe autonomic involvement 
o early severe dementia with disturbances of memory, language and 
praxis 
o Babinski sign 
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o presence of cerebraltumor or communicating hydrocephalus of CT 
scan 
o negative response of large doses of L-Dopa[if malabsorption excluded] 
o MPTP exposure 
STEP 3: supportive prospective positive criteria for PD 
           [3 or more required for diagnosis of definite PD] 
o Unilateral onset 
o Rest tremor 
o Progressive disorder 
o Persistent disorder 
o Persistent asymmetry ,affecting side of onset most 
o Excellent response to L-dopa 
o Severe L-dopa induced chorea 
o L-dopa response for 5 years or more 
o Clinical course of 10 years or more. 
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MODIFIED HOEHN AND YAHR STAGING 
Stage 0 no signs of disease 
Stage 1 unilateral disease 
Stage 1.5 unilateral plus axial involvement 
Stage 2 bilateral disease, without impairment of balance 
Stage 2.5 mild bilateral disease with recovery on pull test 
Stage 3 mild to moderate bilateral disease; some postural instability; 
physically challenged 
Stage 4 severe disability; still able to walk or stand unassisted 
Stage 5 wheel chair bound or bedridden unless aided 
  
80 
 
CLINICAL DIAGNOSTIC CRITERIA FOR PDD BY MOVEMENT 
DISORDER SOCIETY TASK FORCE 
Features of dementia associated with Parkinson’s disease 
I. Core features 
1. Diagnosis of Parkinson‟s disease based on UKPDS Brain Bank clinical 
criteria 
2. A dementia syndrome, which is insidious onset and slowly progressive, 
developing in the context of established Parkinson‟s disease and diagnosed 
by history taking, clinical examination, and neuropsychological testing, 
deﬁned as: 
• Impairment in more than one cognitive domain 
• A decline from premorbid level 
• Deﬁcits severe enough to impair daily life (social, occupational, or personal 
care), independent of the impairment attributable to motor or autonomic 
symptoms 
II. Associated clinical features 
1. Cognitive features: 
• Attention: Impairment in spontaneous and focused attention, poor 
performance in attentional tasks; performance may ﬂuctuate during the day 
and from day to day 
• Executive functions: Impairment in tasks requiring initiation, planning, and 
concept formation, set shifting or set maintenance; impaired mental speed 
(bradyphrenia) 
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• Visuo-spatial functions: Impairment in tasks requiring visual-spatial 
orientation, perception, or construction 
• Memory: Impairment in free recall of recent events or in tasks requiring 
learning new material, and memory usually improves with cues. 
• Language: Word ﬁnding difficulties and impaired comprehension of 
complex sentences. But Core language functions are largely preserved. 
2. Behavioral features: 
• Apathy: loss of motivation, decreased spontaneity, interest, and effortful 
behavior 
• Changes in mood and personality including depressive features and anxiety 
• Hallucinations: usually complex and visual in the form of formed images of 
people, animals or objects 
• Delusions: usually paranoid delusions, such as inﬁdelity, Capgras 
syndrome. 
• Excessive daytime sleepiness 
III. Features which do not exclude PD-D, but make the diagnosis 
uncertain 
• Co-existence of other abnormalities, which may itself cause cognitive 
impairment, but not to be the cause of dementia such as presence of 
periventricular hyperintensities in imaging. 
• Exact time interval between the development of motor and cognitive 
symptoms is not known. 
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IV. Features suggesting other conditions or diseases as cause of mental 
impairment, which, when present make it impossible to reliably diagnose 
PD-D 
• Behavioral and Cognitive symptoms appearing solely in the context of other 
conditions such as, acute confusion due to 
a. Systemic causes 
b. Drug intoxication 
C. Major Depression according to DSM IV 
Criteria for the diagnosis of probable and possible PD-D 
Probable PD-D 
A. Both core features must be present 
B. Associated clinical features: 
             • Cognitive deﬁcits in at least two of the four core cognitive domains 
(impaired attention which may ﬂuctuate, impairment in visuo-spatial 
functions impaired executive functions, and impaired free recall memory 
which usually improves with cues) 
           • The presence of at least one behavioral symptom (apathy, depressed 
or anxious mood, hallucinations, delusions, excessive daytime sleepiness) 
supports the diagnosis of Probable PD-D, lack of behavioral symptoms, 
however, does not exclude the diagnosis  
C. None of the group III features present 
D. None of the group IV features present 
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Possible PD-D 
A. Both core features must be present   
B. Associated clinical features: 
• Atypical cognitive deficits in the form of impairment in one or more 
domains, such as prominent or receptive-type (ﬂuent) aphasia, or pure 
storage-failure type amnesia (memory does not improve with cueing or in 
recognition tasks) with preserved attention 
• Behavioral symptoms may or may not be present 
OR 
C. One or more of the group III features present 
D. None of the group IV features present 
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UNIFIED PARKINSON'S DISEASE RATING SCALE 
(UPDRS) 
I. MENTATION, BEHAVIOR AND MOOD 
1. Intellectual Impairment 
0 = None. 
1 = Mild. Consistent forgetfulness with partial recollection of events and no 
other difficulties. 
2 = Moderate memory loss, with disorientation and moderate difficulty 
handling complex problems. 
Mild but definite impairment of function at home with need of occasional 
prompting. 
3 = Severe memory loss with disorientation for time and often to place. 
Severe impairment in handling problems. 
4 = Severe memory loss with orientation preserved to person only. Unable to 
make judgements 
or solve problems. Requires much help with personal care. Cannot be left 
alone at all. 
2. Thought Disorder (Due to dementia or drug intoxication) 
0 = None. 
1 = Vivid dreaming. 
2 = "Benign" hallucinations with insight retained. 
3 = Occasional to frequent hallucinations or delusions; without insight; 
could interfere with daily activities. 
4 = Persistent hallucinations, delusions, or florrid psychosis. Not able to care 
for self. 
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3. Depression 
0 = None. 
1 = Periods of sadness or guilt greater than normal, never sustained for days 
or weeks. 
2 = Sustained depression (1 week or more). 
3 = Sustained depression with vegetative symptoms (insomnia, anorexia, 
weight loss, loss of interest). 
4 = Sustained depression with vegetative symptoms and suicidal thoughts or 
intent. 
4. Motivation/Initiative 
0 = Normal. 
1 = Less assertive than usual; more passive. 
2 = Loss of initiative or disinterest in elective (nonroutine) activities. 
3 = Loss of initiative or disinterest in day to day (routine) activities. 
4 = Withdrawn, complete loss of motivation. 
II. ACTIVITIES OF DAILY LIVING (for both "on" and "off") 
5. Speech 
0 = Normal. 
1 = Mildly affected. No difficulty being understood. 
2 = Moderately affected. Sometimes asked to repeat statements. 
3 = Severely affected. Frequently asked to repeat statements. 
4 = Unintelligible most of the time. 
6. Salivation 
0 = Normal. 
1 = Slight but definite excess of saliva in mouth; may have nighttime 
drooling. 
2 = Moderately excessive saliva; may have minimal drooling. 
3 = Marked excess of saliva with some drooling. 
4 = Marked drooling, requires constant tissue or handkerchief. 
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7. Swallowing 
0 = Normal. 
1 = Rare choking. 
2 = Occasional choking. 
3 = Requires soft food. 
4 = Requires NG tube or gastrotomy feeding. 
8. Handwriting 
0 = Normal. 
1 = Slightly slow or small. 
2 = Moderately slow or small; all words are legible. 
3 = Severely affected; not all words are legible. 
4 = The majority of words are not legible. 
9. Cutting food and handling utensils 
0 = Normal. 
1 = Somewhat slow and clumsy, but no help needed. 
2 = Can cut most foods, although clumsy and slow; some help needed. 
3 = Food must be cut by someone, but can still feed slowly. 
4 = Needs to be fed. 
10. Dressing 
0 = Normal. 
1 = Somewhat slow, but no help needed. 
2 = Occasional assistance with buttoning, getting arms in sleeves. 
3 = Considerable help required, but can do some things alone. 
4 = Helpless. 
11. Hygiene 
0 = Normal. 
1 = Somewhat slow, but no help needed. 
2 = Needs help to shower or bathe; or very slow in hygienic care. 
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3 = Requires assistance for washing, brushing teeth, combing hair, going to 
bathroom. 
4 = Foley catheter or other mechanical aids. 
12. Turning in bed and adjusting bed clothes 
0 = Normal. 
1 = Somewhat slow and clumsy, but no help needed. 
2 = Can turn alone or adjust sheets, but with great difficulty. 
3 = Can initiate, but not turn or adjust sheets alone. 
4 = Helpless. 
13. Falling (unrelated to freezing) 
0 = None. 
1 = Rare falling. 
2 = Occasionally falls, less than once per day. 
3 = Falls an average of once daily. 
4 = Falls more than once daily. 
14. Freezing when walking 
0 = None. 
1 = Rare freezing when walking; may have starthesitation. 
2 = Occasional freezing when walking. 
3 = Frequent freezing. Occasionally falls from freezing. 
4 = Frequent falls from freezing. 
15. Walking 
0 = Normal. 
1 = Mild difficulty. May not swing arms or may tend to drag leg. 
2 = Moderate difficulty, but requires little or no assistance. 
3 = Severe disturbance of walking, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
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16. Tremor (Symptomatic complaint of tremor in any part of body.) 
0 = Absent. 
1 = Slight and infrequently present. 
2 = Moderate; bothersome to patient. 
3 = Severe; interferes with many activities. 
4 = Marked; interferes with most activities. 
17. Sensory complaints related to parkinsonism 
0 = None. 
1 = Occasionally has numbness, tingling, or mild aching. 
2 = Frequently has numbness, tingling, or aching; not distressing. 
3 = Frequent painful sensations. 
4 = Excruciating pain. 
III. MOTOR EXAMINATION 
18. Speech 
0 = Normal. 
1 = Slight loss of expression, diction and/or volume. 
2 = Monotone, slurred but understandable; moderately impaired. 
3 = Marked impairment, difficult to understand. 
4 = Unintelligible. 
19. Facial Expression 
0 = Normal. 
1 = Minimal hypomimia, could be normal "Poker Face". 
2 = Slight but definitely abnormal diminution of facial expression. 
3 = Moderate hypomimia; lips parted some of the time. 
4 = Masked or fixed facies with severe or complete loss of facial expression; 
lips parted 1/4 inch or more. 
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20. Tremor at rest (head, upper and lower extremities) 
0 = Absent. 
1 = Slight and infrequently present. 
2 = Mild in amplitude and persistent. Or moderate in amplitude, but only 
intermittently present. 
3 = Moderate in amplitude and present most of the time. 
4 = Marked in amplitude and present most of the time. 
21. Action or Postural Tremor of hands 
0 = Absent. 
1 = Slight; present with action. 
2 = Moderate in amplitude, present with action. 
3 = Moderate in amplitude with posture holding as well as action. 
4 = Marked in amplitude; interferes with feeding. 
22. Rigidity (Judged on passive movement of major joints with patient 
relaxed in sitting position. 
Cogwheeling to be ignored.) 
0 = Absent. 
1 = Slight or detectable only when activated by mirror or other movements. 
2 = Mild to moderate. 
3 = Marked, but full range of motion easily achieved. 
4 = Severe, range of motion achieved with difficulty. 
23. Finger Taps (Patient taps thumb with index finger in rapid succession.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests 
in ongoing movement. 
4 = Can barely perform the task. 
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24. Hand Movements (Patient opens and closes hands in rapid succesion.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests 
in ongoing movement. 
4 = Can barely perform the task. 
25. Rapid Alternating Movements of Hands (Pronation-supination 
movements of hands, vertically and 
horizontally, with as large an amplitude as possible, both hands 
simultaneously.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests 
in ongoing movement. 
4 = Can barely perform the task. 
26. Leg Agility (Patient taps heel on the ground in rapid succession picking 
up entire leg. Amplitude 
should be at least 3 inches.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests 
in ongoing movement. 
4 = Can barely perform the task. 
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27. Arising from Chair 
(Patient attempts to rise from a straightbacked chair, with arms folded across 
chest.) 
0 = Normal. 
1 = Slow; or may need more than one attempt. 
2 = Pushes self up from arms of seat. 
3 = Tends to fall back and may have to try more than one time, but can get up 
without help. 
4 = Unable to arise without help. 
28. Posture 
0 = Normal erect. 
1 = Not quite erect, slightly stooped posture; could be normal for older 
person. 
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning 
to one side. 
3 = Severely stooped posture with kyphosis; can be moderately leaning to 
one side. 
4 = Marked flexion with extreme abnormality of posture. 
29. Gait 
0 = Normal. 
1 = Walks slowly, may shuffle with short steps, but no festination (hastening 
steps) or propulsion. 
2 = Walks with difficulty, but requires little or no assistance; may have some 
festination, short steps, 
or propulsion. 
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
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30. Postural Stability (Response to sudden, strong posterior displacement 
produced by pull on shoulders 
while patient erect with eyes open and feet slightly apart. Patient is prepared.) 
0 = Normal. 
1 = Retropulsion, but recovers unaided. 
2 = Absence of postural response; would fall if not caught by examiner. 
3 = Very unstable, tends to lose balance spontaneously. 
4 = Unable to stand without assistance. 
31. Body Bradykinesia and Hypokinesia (Combining slowness, hesitancy, 
decreased armswing, small 
amplitude, and poverty of movement in general.) 
0 = None. 
1 = Minimal slowness, giving movement a deliberate character; could be 
normal for some persons. 
Possibly reduced amplitude. 
2 = Mild degree of slowness and poverty of movement which is definitely 
abnormal. 
Alternatively, some reduced amplitude. 
3 = Moderate slowness, poverty or small amplitude of movement. 
4 = Marked slowness, poverty or small amplitude of movement. 
IV. COMPLICATIONS OF THERAPY (In the past week) 
A. DYSKINESIAS 
32. Duration: What proportion of the waking day are dyskinesias 
present? 
(Historical information.) 
0 = None 
1 = 1-25% of day. 
2 = 26-50% of day. 
3 = 51-75% of day. 
4 = 76-100% of day. 
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33. Disability: How disabling are the dyskinesias? 
(Historical information; may be modified by office examination.) 
0 = Not disabling. 
1 = Mildly disabling. 
2 = Moderately disabling. 
3 = Severely disabling. 
4 = Completely disabled. 
34. Painful Dyskinesias: How painful are the dyskinesias? 
0 = No painful dyskinesias. 
1 = Slight. 
2 = Moderate. 
3 = Severe. 
4 = Marked. 
35. Presence of Early Morning Dystonia (Historical information.) 
0 = No 
1 = Yes 
B. CLINICAL FLUCTUATIONS 
36. Are "off" periods predictable? 
0 = No 
1 = Yes 
37. Are "off" periods unpredictable? 
0 = No 
1 = Yes 
38. Do "off" periods come on suddenly, within a few seconds? 
0 = No 
1 = Yes 
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39. What proportion of the waking day is the patient "off" on average? 
0 = None 
1 = 1-25% of day. 
2 = 26-50% of day. 
3 = 51-75% of day. 
4 = 76-100% of day. 
C. OTHER COMPLICATIONS 
40. Does the patient have anorexia, nausea, or vomiting? 
0 = No 
1 = Yes 
41. Any sleep disturbances, such as insomnia or hypersomnolence? 
0 = No 
1 = Yes 
42. Does the patient have symptomatic orthostasis? 
(Record the patient's blood pressure, height and weight on the scoring form) 
0 = No 
1 = Yes 
V. MODIFIED HOEHN AND YAHR STAGING 
STAGE 0 = No signs of disease. 
STAGE 1 = Unilateral disease. 
STAGE 1.5 = Unilateral plus axial involvement. 
STAGE 2 = Bilateral disease, without impairment of balance. 
STAGE 2.5 = Mild bilateral disease, with recovery on pull test. 
STAGE 3 = Mild to moderate bilateral disease; some postural instability; 
physically independent. 
STAGE 4 = Severe disability; still able to walk or stand unassisted. 
STAGE 5 = Wheelchair bound or bedridden unless aided. 
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VI. SCHWAB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE 
100% = Completely independent. Able to do all chores without slowness, 
difficulty or impairment. 
Essentially normal. Unaware of any difficulty. 
90% = Completely independent. Able to do all chores with some degree of 
slowness, difficulty and 
impairment. Might take twice as long. Beginning to be aware of difficulty. 
80% = Completely independent in most chores. Takes twice as long. 
Conscious of difficulty and 
slowness. 
70% = Not completely independent. More difficulty with some chores. Three 
to four times as long in 
some. Must spend a large part of the day with chores. 
60% = Some dependency. Can do most chores, but exceedingly slowly and 
with much effort. 
Errors; some impossible. 
50% = More dependent. Help with half, slower, etc. Difficulty with 
everything. 
40% = Very dependent. Can assist with all chores, but few alone. 
30% = With effort, now and then does a few chores alone or begins alone. 
Much help needed. 
20% = Nothing alone. Can be a slight help with some chores. Severe invalid. 
10% = Totally dependent, helpless. Complete invalid. 
0% = Vegetative functions such as swallowing, bladder and bowel functions 
are not functioning. 
Bedridden. 
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MASTER CHART 
S.No. Age Age SEX 
Educa
tion 
Durartion 
of illness 
UPDRS 
Hoehn & 
Yahr 
scale 
MMSE 
ACE=R 
attention 
ACE-R 
memory 
ACER- 
fluency 
ACER-
language 
ACER 
visuospa
tial 
ACE-   R 
total 
score 
MOCA 
FAB  
GO-NO-
GO 
FAB 
Lurias 
Test 
FAB 
total 
score 
1.  57 1 M 2 1 1 3 2 2 2 1 2 2 3 2 3 3 2 
2.  58 1 F 1 3 2 2 1 1 1 1 2 1 1 1 1 1 1 
3.  56 1 M 3 1 1 2 2 2 2 2 2 2 3 2 3 3 2 
4.  55 1 F 2 2 1 2 2 2 2 2 2 2 1 2 1 3 2 
5.  58 1 F 1 3 2 3 1 1 1 2 2 1 1 1 2 1 1 
6.  60 1 M 2 1 1 2 2 2 2 1 2 2 3 2 3 3 2 
7.  57 1 M 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
8.  55 1 M 3 1 1 1 2 2 2 2 2 2 3 2 3 3 2 
9.  59 1 M 2 1 1 1 2 2 2 2 2 2 3 2 3 3 2 
10.  70 2 M 1 3 2 3 1 1 1 1 1 1 1 1 1 2 1 
11.  56 1 M 2 1 2 2 1 1 1 1 1 1 1 1 1 1 1 
12.  57 1 M 3 2 2 1 2 2 2 2 2 2 2 2 2 2 2 
13.  58 1 F 2 1 1 1 2 2 2 2 2 2 3 2 3 3 2 
14.  59 1 M 2 1 1 1 2 2 2 2 2 2 3 2 3 3 2 
15.  65 2 M 2 2 2 2 2 2 2 1 2 2 3 2 3 3 2 
16.  70 2 M 1 2 2 3 1 1 1 1 2 1 1 1 1 0 1 
17.  74 3 M 2 2 2 2 1 1 1 1 2 1 2 2 3 3 2 
18.  60 1 M 1 2 2 2 2 2 1 1 2 1 3 2 3 2 2 
19.  57 1 M 2 1 2 2 2 2 2 2 1 2 3 1 2 3 2 
20.  63 2 M 1 3 2 1 1 1 1 1 2 2 1 1 1 2 1 
21.  65 2 M 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 
22.  58 1 M 3 2 1 1 2 2 2 1 2 2 3 2 3 3 2 
23.  65 2 M 2 2 1 2 2 2 2 1 2 2 3 2 3 3 2 
24.  56 1 M 2 2 2 1 2 2 2 1 2 2 3 2 2 2 2 
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S.No. Age Age SEX 
Educa
tion 
Durartion 
of illness 
UPDRS 
Hoehn & 
Yahr 
scale 
MMSE 
ACE=R 
attention 
ACE-R 
memory 
ACER- 
fluency 
ACER-
language 
ACER 
visuospa
tial 
ACE-   R 
total 
score 
MOCA 
FAB  
GO-NO-
GO 
FAB 
Lurias 
Test 
FAB 
total 
score 
25.  62 2 M 2 2 1 2 2 2 1 1 2 1 3 2 3 3 2 
26.  75 3 F 2 3 2 2 1 1 1 1 2 1 1 1 1 1 1 
27.  72 3 F 1 3 2 3 1 1 1 1 2 1 1 1 1 2 2 
28.  66 2 M 2 2 2 2 2 2 2 1 1 2 2 2 2 3 2 
29.  65 2 M 2 2 2 2 1 1 1 1 2 1 1 1 1 1 1 
30.  66 2 M 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 
31.  65 2 M 2 1 1 2 2 2 2 1 2 2 3 2 3 3 2 
32.  57 1 M 2 1 2 1 2 2 2 1 2 2 2 2 3 3 2 
33.  74 3 M 2 3 2 3 1 1 1 1 2 1 1 1 1 1 1 
34.  61 2 M 2 2 2 2 2 2 2 2 1 1 2 2 3 3 2 
35.  55 1 M 2 2 2 3 1 1 1 1 1 1 1 1 2 1 1 
36.  60 1 F 2 2 1 2 2 2 2 1 1 2 3 2 3 3 2 
37.  66 2 F 2 3 3 3 1 1 1 1 1 1 1 1 1 1 1 
38.  58 1 F 2 1 1 1 2 2 2 1 2 2 3 2 3 3 2 
39.  65 2 M 1 2 2 1 2 1 1 1 2 1 2 2 2 3 1 
40.  64 2 F 2 2 2 2 1 1 1 1 1 1 2 2 2 3 2 
41.  66 2 F 2 2 2 1 1 2 2 1 1 2 2 1 2 3 2 
42.  59 1 M 2 2 1 2 2 2 2 1 2 2 2 2 3 2 2 
43.  78 3 M 2 3 2 3 1 1 1 1 1 1 1 1 1 1 1 
44.  60 2 F 2 2 1 1 2 2 2 2 2 1 2 1 3 2 1 
45.  67 2 M 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 
46.  74 3 F 2 3 2 2 1 1 1 2 1 2 1 1 1 2 1 
47.  65 2 M 1 3 2 2 1 1 1 2 2 1 1 1 1 2 1 
48.  64 2 F 1 3 2 2 1 1 1 1 1 2 1 1 1 1 1 
49.  63 2 M 1 2 2 2 1 1 1 1 1 1 1 1 2 3 2 
50.  75 3 M 2 3 2 2 1 1 1 1 1 1 1 1 1 1 1 
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S.No. Age Age SEX 
Educa
tion 
Durartion 
of illness 
UPDRS 
Hoehn & 
Yahr 
scale 
MMSE 
ACE=R 
attention 
ACE-R 
memory 
ACER- 
fluency 
ACER-
language 
ACER 
visuospa
tial 
ACE-   R 
total 
score 
MOCA 
FAB  
GO-NO-
GO 
FAB 
Lurias 
Test 
FAB 
total 
score 
51.  64 2 M 2 3 2 2 1 1 2 2 2 1 1 1 1 1 1 
52.  64 2 F 2 1 1 1 2 2 2 2 2 2 3 2 3 3 2 
53.  59 1 F 2 
 
2 2 1 1 2 2 2 1 2 2 2 3 2 
54.  55 1 F 2 1 1 2 2 2 2 1 2 2 3 2 3 3 2 
55.  70 2 M 2 3 2 3 1 1 1 1 1 1 1 1 2 1 2 
56.  74 3 M 2 2 2 2 1 1 1 1 1 1 1 1 2 1 1 
57.  73 3 F 2 2 2 1 2 2 2 2 2 2 2 2 2 3 2 
58.  62 2 M 2 2 1 2 2 2 2 2 2 2 3 2 3 3 2 
59.  60 1 F 2 2 1 2 2 2 2 2 2 2 3 2 3 3 2 
60.  55 1 M 2 3 3 2 1 1 1 1 2 1 1 1 1 1 1 
61.  68 2 F 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 
62.  58 1 F 1 2 1 1 2 2 1 1 2 1 2 2 2 2 2 
63.  61 2 F 1 3 2 3 1 1 1 1 1 2 1 1 2 2 1 
64.  70 2 M 2 3 2 3 1 1 2 2 2 2 1 1 3 1 2 
65.  76 3 M 1 3 3 2 1 1 2 2 2 2 1 2 2 1 1 
66.  67 2 M 2 2 1 2 2 1 1 1 2 1 3 2 2 2 2 
67.  65 2 M 2 1 1 1 2 2 2 2 2 2 3 2 3 3 2 
68.  72 3 F 2 1 1 1 2 2 2 2 2 2 3 2 3 3 2 
69.  73 3 M 2 2 1 2 2 2 2 2 2 2 2 2 2 3 2 
70.  66 2 F 2 3 2 3 1 1 2 2 1 2 1 1 1 1 1 
71.  56 1 F 2 3 2 2 1 1 2 2 1 2 1 2 1 1 1 
72.  60 1 M 2 3 2 2 1 1 1 1 2 1 1 1 1 2 1 
73.  59 1 F 2 3 2 2 1 1 2 2 1 2 1 1 1 1 1 
74.  63 2 F 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 
75.  67 2 F 2 2 2 1 2 2 2 1 2 2 2 2 2 3 2 
76.  68 2 F 2 3 2 2 1 1 1 1 2 1 1 1 1 1 1 
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S.No. Age Age SEX 
Educa
tion 
Durartion 
of illness 
UPDRS 
Hoehn & 
Yahr 
scale 
MMSE 
ACE=R 
attention 
ACE-R 
memory 
ACER- 
fluency 
ACER-
language 
ACER 
visuospa
tial 
ACE-   R 
total 
score 
MOCA 
FAB  
GO-NO-
GO 
FAB 
Lurias 
Test 
FAB 
total 
score 
77.  63 2 M 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 
78.  55 1 F 2 2 2 1 2 2 2 2 2 2 2 2 2 3 2 
79.  73 3 M 2 2 2 2 2 1 1 1 2 1 2 2 2 3 2 
80.  67 2 F 2 1 2 1 1 1 1 1 1 1 2 1 2 3 2 
81.  65 2 M 2 1 2 2 2 1 1 1 1 1 2 2 2 3 2 
82.  54 1 M 2 2 2 2 2 1 1 1 1 1 2 2 3 3 2 
83.  67 2 F 2 2 2 1 1 1 1 1 1 1 2 2 2 3 2 
84.  59 1 F 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 
85.  58 1 F 2 1 1 1 2 2 2 2 2 2 3 2 3 3 2 
86.  73 2 F 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 
87.  72 2 M 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
88.  65 1 F 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 
89.  65 2 M 2 2 1 2 2 2 2 2 2 2 3 2 3 3 2 
90.  67 2 F 2 2 1 2 2 2 2 2 2 2 3 2 3 3 2 
91.  72 3 M 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 
92.  65 2 M 2 2 1 2 2 2 2 2 2 2 3 2 2 3 2 
93.  66 2 M 1 2 2 1 2 2 2 2 2 1 2 2 3 3 2 
94.  62 2 M 1 3 2 2 2 2 2 2 2 2 1 2 1 1 1 
95.  71 3 M 1 1 1 2 2 2 2 2 2 1 3 2 3 3 2 
96.  79 3 M 1 3 3 3 1 1 1 1 1 1 1 2 1 1 1 
97.  66 2 M 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 
98.  68 2 F 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 
99.  60 1 M 1 2 2 1 2 2 2 1 1 2 3 2 2 3 2 
100.  61 2 F 2 1 1 2 2 2 2 2 2 2 3 2 3 3 2 
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KEY TO MASTER CHART 
 
Age  
1= 55-60 years  
2=61-70 years  
3= 71-75 years  
Sex  
M= Male  
F= Female  
 
Education  
1=Illiterate and studied up to elementary school  
2= Studied up to secondary school 
3= degree holder 
 
Duration of the illness  
1= less than 5 years  
2= 5 to 10 years  
3= more than 10 years  
 
UPDRS 
 1= < 30 
 2= 31 to 60 
3= > 60 
 
Hoehn & Yahr score 
1= < 1.5 
2= 2 to 3 
3= 4 to 5 
 
MMSE= Mini Mental State Examination score  
1=<23  
2=>23  
 
ACE-R- ADDENBROOKES COGNITION SCALE  
ACE-R Attention and orientation  
1= <12  
2= 13 to 18  
 
ACE-R Memory  
1= <18  
2=18to 26  
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ACE-R Fluency  
1= <8  
2= 9 to 14  
 
ACE-R Language  
1=<18  
2=18 to 24  
 
ACE-R Visuospatial  
1=<10  
2= 11 TO 16  
 
ACE-R Total score  
1=<60  
2=61 to 80  
3=81 to 100  
 
MOCA 
 1= < 23 
 2= > 23 
 
FAB Lurias test  
3 =Patient performs six correct consecutive series alone:  
2= Patient performs at least three correct consecutive series alone:  
1= Patient fails alone, but performs three correct consecutive series 
with the examiner:  
0=Patient cannot perform three correct consecutive series even with the 
examiner:  
 
FAB Go-no-Go test  
3=No errors  
2= 1 -2 errors  
1= > 2 errors  
 
FAB Total score  
1= <12,  
2= 13 to 18 
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